Education
About Us
Working with TipRanks
Follow Us
China Medical System Holdings Ltd. (HK:0867)
:0867
0867 Stock Chart & Stats
HK$14.20
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$14.20
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$6.84 - HK$15.63
Previous CloseN/A
Volume2.83M
Average Volume (3M)6.44M
Market Cap
HK$37.40B
Enterprise ValueHK$30.06B
Total Cash (Recent Filing)HK$5.97B
Total Debt (Recent Filing)HK$747.60M
Price to Earnings (P/E)20.9
Beta0.85
Next Earnings
Mar 17, 2026EPS Estimate
0.33Next Dividend Ex-DateN/A
Dividend Yield2.26%
Share Statistics
EPS (TTM)0.44
Shares Outstanding2,439,528,600
10 Day Avg. Volume4,711,227
30 Day Avg. Volume6,437,247
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)1.06
Price to Sales (P/S)2.30
P/FCF Ratio21.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$17.34Price Target Upside22.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthLow leverage and a high equity ratio provide durable financial flexibility, allowing the company to fund product lifecycle investments, M&A or withstand reimbursement pressure. This stability supports long-term operations and reduces refinancing or solvency risk over the next 2–6 months.
Commercialization & Distribution CapabilitiesDirect sales presence across hospital and retail channels plus life-cycle management expertise gives structural competitive advantage in China. This durable commercial footprint supports market access for new in-licensed products and helps sustain revenue capture and margin conversion over time.
Strong Gross & EBITDA MarginsSustained gross margins and decent EBITDA margins indicate underlying product profitability and cost control, enabling reinvestment in R&D and commercialization. Combined with a robust free-cash-flow-to-net-income ratio, the company retains cash conversion capability despite revenue weakness.
Bears Say
Declining Revenue And ProfitabilityTwo consecutive years of revenue decline and lower net margins signal weakening demand or portfolio challenges. This erosion reduces scale economics and limits internal funding for development and market expansion, posing a sustained headwind to earnings recovery absent new product wins.
Operating Cash Flow DeteriorationSignificantly lower operating cash flow undermines the firm's ability to fund capex, acquisitions or working capital from operations. Even with solid FCF-to-net-income ratios, falling absolute cash generation constrains strategic flexibility and increases reliance on balance sheet buffers.
Reliance On In-licensing And AcquisitionsA growth model dependent on in-licensing and acquisitions is capital intensive and exposes the company to deal execution, integration and royalty dilution risks. Long-term success requires consistent deal flow and integration capability, which can be uneven and strain margins if outcomes disappoint.
China Medical System Holdings News
0867 FAQ
What was China Medical System Holdings Ltd.’s price range in the past 12 months?
China Medical System Holdings Ltd. lowest stock price was HK$6.84 and its highest was HK$15.63 in the past 12 months.
What is China Medical System Holdings Ltd.’s market cap?
China Medical System Holdings Ltd.’s market cap is HK$37.40B.
When is China Medical System Holdings Ltd.’s upcoming earnings report date?
China Medical System Holdings Ltd.’s upcoming earnings report date is Mar 17, 2026 which is in 25 days.
How were China Medical System Holdings Ltd.’s earnings last quarter?
China Medical System Holdings Ltd. released its earnings results on Aug 18, 2025. The company reported HK$0.44 earnings per share for the quarter, beating the consensus estimate of HK$0.419 by HK$0.021.
Is China Medical System Holdings Ltd. overvalued?
According to Wall Street analysts China Medical System Holdings Ltd.’s price is currently Undervalued.
Does China Medical System Holdings Ltd. pay dividends?
China Medical System Holdings Ltd. pays a Semiannually dividend of HK$0.171 which represents an annual dividend yield of 2.26%. See more information on China Medical System Holdings Ltd. dividends here
What is China Medical System Holdings Ltd.’s EPS estimate?
China Medical System Holdings Ltd.’s EPS estimate is 0.33.
How many shares outstanding does China Medical System Holdings Ltd. have?
China Medical System Holdings Ltd. has 2,439,528,600 shares outstanding.
What happened to China Medical System Holdings Ltd.’s price movement after its last earnings report?
China Medical System Holdings Ltd. reported an EPS of HK$0.44 in its last earnings report, beating expectations of HK$0.419. Following the earnings report the stock price went down -0.743%.
Which hedge fund is a major shareholder of China Medical System Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:0867
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
China Medical System Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.75%
12-Months-Change
Fundamentals
Return on Equity
10.01%
Trailing 12-Months
Asset Growth
5.81%
Trailing 12-Months
Company Description
China Medical System Holdings Ltd.
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company's products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu for treating respiratory diseases; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications. In addition, the company also offers Elcatonin injection for osteoporosis; YinlianQinggan granules for treating acute hepatitis A and chronic hepatitis B; Lamisil tablets for treating fungal infections on skin and hair; and MOVICOL for treating chronic constipation and faecal impaction. In addition, it is involved in the agriculture and livestock activities. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.
0867 Stock 12 Month Forecast
Average Price Target
HK$17.34
▲(22.14% Upside)
Technical Analysis
The United Laboratories International Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Grand Pharmaceutical Group Limited
―
Options Prices
Currently, No data available
---